Real-world analysis of the Celgene Global Drug Safety database: early discontinuation of lenalidomide in patients with myelodysplastic syndromes due to non-serious rash

BACKGROUND: Lenalidomide is approved for treating transfusion-dependent anemia due to lower-risk del(5q) myelodysplastic syndromes (MDS). In clinical trials, rash was common, although severe rash was infrequent. To examine rash in patients with MDS treated with lenalidomide in the real world, the Ce...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Clin Risk Manag
Main Authors: Weiss, Lilia, Gary, Dianna, Swern, Arlene S, Freeman, John, Sugrue, Mary M
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2015
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4567225/
https://ncbi.nlm.nih.gov/pubmed/26379438
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S86449
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados